Drug resistant TB – latest developments in epidemiology, diagnostics and management

•DR- and MDR-TB are more frequent in contacts and patients previously treated.•Whole genome sequencing, rapid, consistent and sensitive, is very useful in outbreaks•RR/MDR-TB requires treatment with ≥4 drugs for 6–24 months.•An all oral shorter WHO course is now recommended for the treatment of RR-T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International journal of infectious diseases Ročník 124; s. S20 - S25
Hlavní autoři: Tiberi, Simon, Utjesanovic, Natasa, Galvin, Jessica, Centis, Rosella, D'Ambrosio, Lia, van den Boom, Martin, Zumla, Alimuddin, Migliori, Giovanni Battista
Médium: Journal Article
Jazyk:angličtina
Vydáno: Canada Elsevier Ltd 01.11.2022
Elsevier
Témata:
Active TB drug safety monitoring (aDSM)
Adherence
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
BPaL
Drug susceptibility testing (DST)
Drug-resistant TB (DR-TB)
Extensively Drug-Resistant Tuberculosis - diagnosis
Extensively Drug-Resistant Tuberculosis - drug therapy
Extensively Drug-Resistant Tuberculosis - epidemiology
Humans
Isoniazid - therapeutic use
Mycobacterium tuberculosis - genetics
Rehabilitation
Rifampin - therapeutic use
Treatment Guidelines
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Video Observed Therapy (VOT)
WHO shorter oral regimen
Adherence
Treatment Guidelines
BPaL
Video Observed Therapy (VOT)
WHO shorter oral regimen
Rehabilitation
Drug-resistant TB (DR-TB)
Drug susceptibility testing (DST)
Active TB drug safety monitoring (aDSM)
ISSN:1201-9712, 1878-3511, 1878-3511
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:•DR- and MDR-TB are more frequent in contacts and patients previously treated.•Whole genome sequencing, rapid, consistent and sensitive, is very useful in outbreaks•RR/MDR-TB requires treatment with ≥4 drugs for 6–24 months.•An all oral shorter WHO course is now recommended for the treatment of RR-TB.•Pulmonary rehabilitation is useful for patients with sequelae. The aim of this review is to inform the reader on the latest developments in epidemiology, diagnostics and management. Drug-resistant Tuberculosis (DR-TB) continues to be a current global health threat, and is defined by higher morbidity and mortality, sequelae, higher cost and complexity. The WHO classifies drug-resistant TB into 5 categories: isoniazid-resistant TB, rifampicin resistant (RR)-TB and MDR-TB, (TB resistant to isoniazid and rifampicin), pre-extensively drug-resistant TB (pre-XDR-TB) which is MDR-TB with resistance to a fluoroquinolone and finally XDR-TB that is TB resistant to rifampicin, plus any fluoroquinolone, plus at least one further priority A drug (bedaquiline or linezolid). Of 500,000 estimated new cases of RR-TB in 2020, only 157 903 cases are notified. Only about a third of cases are detected and treated annually. Recently newer rapid diagnostic methods like the GeneXpert, whole genome sequencing and Myc-TB offer solutions for rapid detection of resistance. The availability of new TB drugs and shorter treatment regimens have been recommended for the management of DR-TB. Despite advances in diagnostics and treatments we still have to find and treat two thirds of the drug resistant cases that go undetected and therefore go untreated each year. Control of TB and elimination will only occur if cases are detected, diagnosed and treated promptly.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2022.03.026